Medicine and Dentistry
Hematopoietic Stem Cell
100%
Cell Transplantation
82%
Acute Myeloid Leukemia
77%
Overall Survival
76%
Allogeneic Stem Cell Transplantation
69%
Mortality Rate
47%
Immunosuppressive Treatment
44%
Decitabine
35%
Aortic Aneurysm
35%
Allotransplantation
35%
Abdominal Aortic Aneurysm
35%
Myelofibrosis
35%
Programmed Cell Death
35%
Microenvironment
35%
Myeloid Malignancy
35%
Aneurysm Surgery
35%
Acute Myelogenous Leukemia
35%
Stem Cell Therapy
35%
Erythroid Cell
35%
Minimal Residual Disease
35%
Cancer
35%
Hypomethylating Agent
35%
Myelodysplastic Syndrome
35%
Human Parainfluenza Virus 3
35%
Hematopoietic Stem Cell
35%
Cyclophosphamide
35%
Cohort Analysis
35%
Adult Hematology
35%
Infection Control
35%
Molecular Epidemiology
35%
Prospective Study
35%
Hyperglycemia
35%
Immune Deficiency
35%
Disseminated Herpes Zoster
35%
Immunogenicity
35%
Graft Versus Host Reaction
34%
Transplantation
27%
Survival Rate
25%
Aneurysm
20%
Recurrence Free Survival
20%
Mononuclear Cell
17%
Autophagy
17%
Funnel Plot
17%
Erythroblast
17%
Precursor
17%
Solid Malignant Neoplasm
17%
Logistic Regression Analysis
11%
Postoperative Complication
11%
Hematology
11%
Hemagglutinin
11%
Keyphrases
Pretransplant
35%
Conventional Chemotherapy
35%
Older AML
35%
Acute Myeloid Leukemia
35%
Minimal Residual Disease
35%
Allogeneic Hemopoietic Stem Cell Transplantation
35%
Decitabine
35%
Erythroid Cells
35%
Microenvironment
35%
Older Patients
35%
Low-risk Myelodysplastic Syndromes
35%
Erythroid Progenitors
35%
Oral mucosa
35%
Ruxolitinib
35%
Quality Assessment
35%
Complex EVAR
35%
Abdominal Aortic Aneurysm Surgery
35%
Steroid-refractory
35%
Bovine Parainfluenza Virus Type 3 (BPIV3)
35%
Graft-versus-host Disease (GvHD)
35%
Mobilization Failure
35%
Oral Participation
35%
Hospital Compare
35%
Failure to Rescue
35%
Mortality Rate
35%
Team Quality
35%
Netherlands
35%
Continuous Glucose Monitoring
35%
Severe Hyperglycemia
35%
Secondary Immunodeficiency
35%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
Poor Mobilizers
23%
Hyperglycemia
20%
Erythroblasts
17%
Apoptosis
17%
Autophagy
17%
Cellular Context
17%
Hematopoietic Cells
17%
Programmed Cell Death
17%
Precursor Cells
17%
Mononuclear Cell Fraction
17%
Myelodysplastic
17%
Poor Mobilization
17%
Major Complications
16%
Intensive Chemotherapy
15%
Hemagglutinin-neuraminidase Gene
11%
Reduced Immunogenicity
11%
Immune Treatment
11%
Hospital Volume
10%
Glucose Level
10%
Immunology and Microbiology
Hematopoietic Cell
85%
Myeloid
82%
Cell Transplantation
73%
Overall Survival
47%
Immunodeficiency
35%
Allotransplantation
35%
Mouth Mucosa
35%
Stem Cell
35%
Human Parainfluenza Virus 3
35%
Cyclophosphamide
35%
Molecular Epidemiology
35%
Immunogenicity
35%
Hematopoiesis
35%
Chronic Graft Versus Host Disease
35%
Graft-Versus-Host Disease
29%
Immunosuppressive Drug
23%
Transplant Procedure
23%
Herpes Zoster
23%
Allogeneic Stem Cell Transplantation
23%
Survival Rate
23%
Recurrence Free Survival
17%
Hemagglutinin-Neuraminidase
11%
Gene Frequency
11%
Subunit Vaccine
11%
Varicella Zoster Virus
11%
Human Immunodeficiency Virus
11%
B Cell
11%
Vaccination Schedule
11%
Rituximab
11%
Conditioning
5%
CD34
5%
Next Generation Sequencing
5%
Comorbidity
5%
